two pore segment channel 2Genealiases: SHEP10 · TPC2
Q-omics provides the consensus-scored TPCN2 profile across patient tissues and cancer cell-line models. TPCN2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TPCN2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TPCN2 RNA expression shows 19,526 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TPCN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPCN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPCN2 survival associations across molecular data types. TPCN2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPCN2 RNA expression–survival associations across cancer types. High TPCN2 expression shows unfavorable associations in ACC, HNSC, CESC, OV and LUSC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TPCN2 RNA expression.
This table summarizes TPCN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TPCN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPCN2 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in KIRC, HNSC and CHOL. The KIRC box plot shows higher TPCN2 RNA expression in tumor versus normal tissue (log2 FC = +1.029, t-test p < 0.001).
This table shows molecular features associated with TPCN2 in patient tissues and cancer cell lines. In patient samples, TPCN2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPCN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
